Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  3SBio Inc. (ADR)    YFK

No quotes available
-- EUR   0.00%
07/08 3SBIO : gets nod for colorectal cancer drug clinical trial
06/03 3SBIO INC. : (01530) says ITP drug get clinical trial approval
05/20 3SBIO INC. : (01530) withdraws breast cancer drug application
SummaryQuotesNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M CNY Estimates in M CNY
Fiscal Period December 201320142015201620172018
Sales--1 6732 7523 3844 159
Operating income (EBITDA)--6921 1031 3611 567
Operating profit (EBIT)--6149141 1411 324
Pre-Tax Profit (EBT)------
Net income--5267839911 256
P/E ratio--39,622,117,213,4
EPS ( CNY )--0,230,310,400,52
Dividend per Share ( CNY )----0,010,01
Yield----0,12%0,15%
Reference price ( CNY )9.116.888136.888136.88813
Announcement Date--03/31/2016
11:12am
---
Finances - Leverage
Actuals in M CNY Estimates in M CNY
Fiscal Period December 201320142015201620172018
Debt---760--
Finance--894-43,51 022
Operating income (EBITDA)--6921 1031 3611 567
Leverage
(Debt/EBITDA)
---0,69x--
Capital Expenditure--61,0124129108
Book Value Per Share (BVPS)--2,24  CNY2,36  CNY2,74  CNY3,45  CNY
Cash Flow per Share--0,20  CNY0,36  CNY0,35  CNY0,57  CNY
Announcement Date01/01/1970
01:00am
01/01/1970
01:00am
03/31/2016
11:12am
---
Balance Sheet Analysis
Assessed data source :
© 2016 Thomson Reuters
Advertisement
Financial Ratios

Size 2016e 2017e
Capitalization 17 435 M CNY -
Entreprise Value (EV) 18 196 M CNY 17 392 M CNY
Valuation 2016e 2017e
P/E ratio (Price / EPS) 22,1x 17,2x
Capitalization / Revenue 6,34x 5,15x
EV / Revenue 6,61x 5,14x
EV / EBITDA 16,5x 12,8x
Yield (DPS / Price) - 0,12%
Price to book (Price / BVPS) 2,92x 2,51x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) 33,2% 33,7%
operating Leverage (Delta EBIT / Delta Sales) 0,76x 1,08x
Net Margin (Net Profit / Revenue) 28,4% 29,3%
ROA (Net Profit / Asset) 9,39% 9,77%
ROE (Net Profit / Equities) 12,6% 14,6%
Rate of Dividend - 2,00%
Balance Sheet Analysis 2016e 2017e
CAPEX / Sales   4,51% 3,81%
Cash Flow / Sales 32,6% 26,3%
Capital Intensity (Assets / Sales) 3,03x 3,00x
Financial Leverage (Net Debt / EBITDA) 0,69x -0,03x
Price Earning Ratio Help 
The blue ligne is the average P/E ratio (without estimates)
EPS & Dividend